Evidence map›Paper›PMID 30883995›Full record

ArticleGenes, chromosomes & cancer2019

Germline large deletion of BAP1 and decreased expression in non-tumor choroid in uveal melanoma patients with high risk for inherited cancer.

Getachew Boru, Timothy W Grosel, Robert Pilarski, Meredith Stautberg, James B Massengill, Joanne Jeter, Arun Singh, Meghan J Marino, Joseph P McElroy, Frederick H Davidorf and 2 more

Open access · greenAbstract read
In one paragraph

Article in Genes, chromosomes & cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. An overview of BAP1 biological functions and current therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2025
    Review
  3. Article
  4. Diagnostics ofDiagnostics (Basel, Switzerland) · 2022
    Article
  5. Germ LineOcular oncology and pathology · 2021
    Article
  6. Review
  7. Article
  8. Melanoma susceptibility: an update on genetic and epigenetic findings.International journal of molecular epidemiology and genetics · 2021
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Getachew BoruDepartment of Ophthalmology and Visual Science, Havener Eye Institute, The Ohio State University Columbus, Columbus, Ohio.
Timothy W GroselDepartment of Ophthalmology and Visual Science, Havener Eye Institute, The Ohio State University Columbus, Columbus, Ohio.
Robert PilarskiDivision of Human Genetics, Department of Internal Medicine, The Ohio State University Columbus, Columbus, Ohio.
Meredith StautbergDivision of Human Genetics, Department of Internal Medicine, The Ohio State University Columbus, Columbus, Ohio.
James B MassengillDepartment of Ophthalmology and Visual Science, Havener Eye Institute, The Ohio State University Columbus, Columbus, Ohio.
Joanne JeterDivision of Human Genetics, Department of Internal Medicine, The Ohio State University Columbus, Columbus, Ohio.
Arun SinghCole Eye Institute, Department of Ophthalmic Oncology, Cleveland Clinic, Cleveland, Ohio.
Meghan J MarinoCole Eye Institute, Department of Ophthalmic Oncology, Cleveland Clinic, Cleveland, Ohio.
Joseph P McElroyCenter for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
Frederick H DavidorfDepartment of Ophthalmology and Visual Science, Havener Eye Institute, The Ohio State University Columbus, Columbus, Ohio.
Colleen M CebullaDepartment of Ophthalmology and Visual Science, Havener Eye Institute, The Ohio State University Columbus, Columbus, Ohio.
Mohamed H Abdel-RahmanDepartment of Ophthalmology and Visual Science, Havener Eye Institute, The Ohio State University Columbus, Columbus, Ohio.ORCID 0000-0002-9493-7894
Columbus Eye Surgery Center · USThe Ohio State University · USCleveland Clinic · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Genetic polymorphisms in retinal detachment with proliferative vitreoretinopathyK08EY022672 · NEI · OHIO STATE UNIVERSITY · PI CEBULLA, COLLEEN MARIE · 2012 to 2016
$1.1M
Hereditary cancer predisposition syndromes and uveal melanomaR21CA191943 · NCI · OHIO STATE UNIVERSITY · PI ABDEL-RAHMAN, MOHAMED H. · 2015 to 2016
$368k
Evaluation of an OCA2 enhancer variant as a modifier of the phenotype of BAP1-Tumor predisposition syndromeR21CA219884 · NCI · OHIO STATE UNIVERSITY · PI ABDEL-RAHMAN, MOHAMED H. · 2018 to 2019
$368k
NCI NIH HHS P30 CA016058NCI NIH HHS R21 CA191943NCI NIH HHS R21 CA219884NEI NIH HHS K08 EY022672
6 · The paper itself

Abstract

Uveal melanoma (UM) is the most common phenotype in patients with germline BAP1 mutation. This study aimed to identify selection criteria for BAP1 germline testing and assessed the role of large deletion/duplication and epigenetic inactivation. One hundred seventy-two UM patients with high risk of hereditary cancer were included. Germline variants in BAP1 were assessed by direct sequencing and large deletion/duplication by multiplex ligation-dependent probe amplification. BAP1 expression in unaffected choroid tissue from a patient with UM was assessed by quantitative RT-PCR and methylation by pyrosequencing. Twenty-eight patients had one or more germline sequence variants in BAP1; seven of these were pathogenic. One hundred forty patients were assessed for large deletion/duplication and in one BAP1 whole gene deletion was detected. In total, eight patients (4.7%) had pathogenic alterations in BAP1 with the highest frequencies of in patients with a personal/family history of ≥2 BAP1-related cancers 6/16 (38%), age of onset <35 years 4/21 (19%) and familial UM 6/34 (18%). One of 19 non-tumor choroid tissues tested showed uncharacteristically low expression as compared to the controls decrease in BAP1 RNA expression but no evidence of constitutional promotor hypermethylation was detected. UM patients with a strong personal or family history of cancers associated with BAP1, early age of onset and familial UM should be assessed for germline variants in BAP1, including large deletions.

Indexed as

Gene DeletionGerm-Line MutationAdolescentAdultAgedAged, 80 and overChildChild, PreschoolChoroidFemaleHumansInfantMaleMelanomaMiddle AgedRNA, MessengerBAP1 protein, humanRNA, MessengerTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1germlineuveal melanomawhole gene deletion

Identifiers

PMID30883995
PMCPMC6612571
OpenAlexW2922741346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.